Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine
Tóm tắt
Từ khóa
Tài liệu tham khảo
Javle M, Hsueh CT: Recent advances in gastrointestinal oncology—updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol 2010. 2009, 23 (3): 11-23.
Waerner T, Urthaler J, Krapfenbauer K: The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicine. EPMA J. 2010, 1: 619-626. 10.1007/s13167-010-0053-y.
Golubnitschaja O, Costigliola V, EPMA: General reports & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012, 3: 14-10.1186/1878-5085-3-14.
Issaq HJ, Waybright TJ, Veenstra TD: Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis. 2011, 32 (9): 967-975. 10.1002/elps.201000588.
Amur S, Frueh FW, Lesko LJ, Huang SM: Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med. 2008, 2 (3): 305-311. 10.2217/17520363.2.3.305.
Feuerstein GZ, Dormer C, Rufollo RR, Stiles G, Walsh FS, Rutkowski JL: Translational medicine perspectives of biomarkers in drug discovery and development. Part I. Target selection and validation - biomarkers take center stage. Int Drug Discovery. 2007, 2 (5): 36-43.
Bruenner N: What is the difference between “predictive and prognostic biomarkers”? Can you give some examples?. Connection. 2009, 13: 18-
Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A: Biomarkers and surrogate end points - the challenge of statistical validation. Nat Rev Clin Oncol. 2007, 7 (6): 309-317.
Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A: Integrating biomarkers in clinical trials. Expert Rev Mol Diagn. 2011, 11 (2): 171-182. 10.1586/erm.10.120.
Rosenkranz B: Biomarkers and surrogate end points in clinical drug development. Appl Clin Trials. 2003, 5 (2): 30-40.
Lassere MN, Johnson KR, Boers M: Definitions and validation criteria for biomarkers and surrogate end points: development and testing of a quantitative hierarchical level of evidence schema. J Rheumatol. 2007, 34 (3): 607-615.
Atkinson AJ, Colburn WA, DeGruttola VG: Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001, 69 (3): 89-95.
Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003, 2 (7): 566-580. 10.1038/nrd1130.
Zolg W: The proteomic search for diagnostic biomarkers: molecular & cellular. Proteomics. 2006, 5: 10-1720–1726
Goodsaid FM, Mendrick DL: Translational medicine and the value of biomarker qualification. Sci Transl Med. 2010, 2 (47): 47-
Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001, 93: 1054-1061. 10.1093/jnci/93.14.1054.
Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A: Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol. 2009, 43: 461-466. 10.3109/00365590903296837.
Lawton KA, Berger A, Mitchell M, Milgram KE, Evans AM, Guo L, Hanson RW, Kalhan SC, Ryals JA, Milburn MV: Analysis of the adult human plasma metabolome. Pharmacogenomics. 2008, 9: 383-397. 10.2217/14622416.9.4.383.
Grossman HB: Are biomarkers for bladder cancer beneficial?. J Urol. 2010, 183: 11-12. 10.1016/j.juro.2009.10.052.
Want EJ, O’Maille G, Smith CA, Brandon TR, Uritboonthai W, Qin C, Trauger SA, Siuzdak G: Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem. 2006, 78: 743-752. 10.1021/ac051312t.
Xiao Z, Conrads TP, Lucas DA, Janini GM, Schaefer CF, Buetow KH, Issaq HJ, Veenstra TD: Direct ampholyte-free liquid-phase isoelectric peptide focusing: application to the human serum proteome. Electrophoresis. 2004, 25: 128-133. 10.1002/elps.200305700.
Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A: The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics. 2004, 3: 311-326. 10.1074/mcp.M300127-MCP200.
Buscher JM, Czernik D, Ewald JC, Sauer U, Zamboni N: Cross-platform comparison of methods for quantitative metabolomics of primary metabolism. Anal Chem. 2009, 81: 2135-2143. 10.1021/ac8022857.
Sleigh S, Barton C: Advances in Drug-Diagnostic Co-Development. 2011, London: Scrip Business Insights
Ausweger C, Burgschwaiger E, Kugler A, Schmidbauer R, Steinek I, Todorov Y, Thurnher D, Krapfenbauer K: Economic concerns about global healthcare in lung, head and neck cancer: meeting the economic challenge of predictive, preventive and personalized medicine. EPMA J. 2010, 1 (4): 627-631. 10.1007/s13167-010-0054-x.